BioCentury | Feb 21, 2020
Product Development

Gilead beefing up Corp Dev with new SVP role

Gilead is creating an SVP of corporate development position, a signal to investors that the company is answering the call for increased M&A. According to a posting on several recruitment sites, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Feb 10, 2020
Politics, Policy & Law

Trump budget request claims $135B in drug savings, calls for NIH cut that won’t happen, flatlines FDA

President Donald Trump’s FY21 budget includes provisions the administration says will save $135 billion in drug costs over 10 years. The White House recycled ideas it has proposed over the last two years but did...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

Biotech indexes rose as much as 33% in 2019 despite gaining little value overall in the year’s first nine months, with a series of clinical catalysts and strong appetite for M&A and licensing deals fueling...
BC Extra | Dec 10, 2019
Clinical News

ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BC Extra | Oct 24, 2019
Financial News

Lilly shares slide amid Trulicity, Taltz pricing concerns

Shares of Eli Lilly slid Wednesday after the company reported weaker-than-expected 3Q19 sales for drugs affected by high rebates and discounts. Eli Lilly and Co. (NYSE:LLY) lost $2.4 billion in market cap, closing the day...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
Items per page:
1 - 10 of 661